F/m Emerald Life Sciences Innovation ETF (NASDAQ:LFSC – Get Free Report) was the target of a significant drop in short interest in September. As of September 30th, there was short interest totaling 5,613 shares, a drop of 77.2% from the September 15th total of 24,651 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average daily volume of 3,199 shares, the short-interest ratio is presently 1.8 days.
F/m Emerald Life Sciences Innovation ETF Stock Performance
LFSC stock traded down $0.59 during trading on Monday, hitting $42.02. The company had a trading volume of 1,103 shares, compared to its average volume of 4,299. The firm has a 50-day moving average price of $45.67 and a 200-day moving average price of $42.18. F/m Emerald Life Sciences Innovation ETF has a 12 month low of $29.55 and a 12 month high of $48.78.
Institutional Investors Weigh In On F/m Emerald Life Sciences Innovation ETF
An institutional investor recently raised its stake in F/m Emerald Life Sciences Innovation ETF stock. Hunter Associates Investment Management LLC lifted its position in shares of F/m Emerald Life Sciences Innovation ETF (NASDAQ:LFSC – Free Report) by 8.3% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 49,739 shares of the company’s stock after acquiring an additional 3,831 shares during the quarter. Hunter Associates Investment Management LLC owned approximately 1.86% of F/m Emerald Life Sciences Innovation ETF worth $1,736,000 at the end of the most recent reporting period.
F/m Emerald Life Sciences Innovation ETF Company Profile
The F/M Emerald Life Sciences Innovation ETF (LFSC) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed ETF that targets US health care and biotechnology companies identified to have promising life sciences opportunities. LFSC was launched on Oct 31, 2024 and is issued by F/m Investments.
See Also
- Five stocks we like better than F/m Emerald Life Sciences Innovation ETF
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
Receive News & Ratings for F/m Emerald Life Sciences Innovation ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for F/m Emerald Life Sciences Innovation ETF and related companies with MarketBeat.com's FREE daily email newsletter.
